Tags : China


Eli Lilly Signs an Exclusive License Agreement with SciNeuro to

Shots: Lilly to receive up front, milestones, as well as royalties on the products developed and commercialize by SciNeuro. Lilly retains all rights outside Greater China SciNeuro to get an exclusive license to develop and commercialize alpha-synuclein targeted therapies in Greater China includes mainland China, Hong Kong, Macau, And Taiwan Alpha-synuclein directed therapies help to […]Read More

Biosimilars M&A

WuXi Biologics to Acquire Pfizer’s Biologics Manufacturing Facilities in China

Shots: WuXi Biologics signs an equity agreement with Pfizer to acquire its state-of-the-art biologics manufacturing facilities along with its labor force in Hangzhou, China. The transaction is expected to close in H1’21 The agreement will boost WuXi Biologics’ commercial DS & DP capabilities to address surging manufacturing demands The state-of-the-art 50,000 m2 facilities include DS […]Read More


Thermo Fisher Collaborates with JW Therapeutics for CAR-T Therapies in

Shots: The companies signed an agreement to ensure non-exclusive commercial access to Thermo Fisher’s Gibco CTS Dynabeads CD3/CD28 The focus of the agreement is to support clinical development & commercial manufacturing of leading CAR-T therapies in China including JW’s relmacabtagene autoleucel (relma-cel) Relma-cel is an anti-CD19 CAR-T therapy for 3L treatment for r/r B-cell lymphoma […]Read More


Innovent’s Byvasda (biosimilar, bevacizumab) Receives NMPA’s Approval for the Treatment

Shots: The indication is the third indication approved for the therapy, previously it was approved for advanced NSCLC and metastatic colorectal cancer The launch of Byvasda has provided Chinese patients with high quality and relatively more affordable bevacizumab biosimilar injection Byvasda is an anti -VEGF humanized mAb. In Jan’2020, Innovent out-licensed the commercial rights of […]Read More


AstraZeneca’s Trixeo Aerosphere Receives EU’s Approval for the Maintenance Treatment

Shots: The approval is based on P-lll ETHOS involve the assessing of Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) vs Bevespi Aerosphere and PT009 in adult patients with mod. to sev. COPD. P-III KRONOS study also supported the approval The study showed a reduction in rate of mod. or sev. exacerbations. EMA’s CHMP has recommended the MAA […]Read More


Alvotech and Alvotech & CCHT Sign an Exclusive Commercialization Agreement

Shots: The companies collaborate with the Yangtze to commercialize eight biosimilars in China. The initial pipeline contains biosimilar candidates for the treatment of autoimmunity, ophthalmology, and oncology Alvotech and Alvotech & CCHT will be jointly responsible for the development, registration, and supply of biosimilars in China while Yangtze River Pharmaceutical will exclusively commercialize the biosimilars […]Read More


Innovent’s Sulinno (biosimilar, adalimumab) Receive NMPA’s Approval for Polyarticular Juvenile

Shots: The NMPA has approved Sulinno for the treatment of pJIA which is the fourth approved indication of the therapy in China. Earlier, Sulinno was approved for RA, PS, and psoriasis The launch of Sulinno has provided more Chinese patients with high-quality and relatively affordable adalimumab injection, bringing hope and opportunities to more patients Sulinno […]Read More


Bayer and 111 Collaborate to Explore the Vast Blue Ocean

Shots: The companies will collaborate on drug commercialization initiatives in China, including the commercialization of innovative drugs & healthcare products for chronic disease management, as well as providing reliable and convenient resources for patient education Bayer will leverage 111’s vast network of pharmacies and healthcare providers to enhance its channel management and patient outreach capabilities, […]Read More